Descrizione del progetto
L’IA per guidare il trattamento dell’anemia falciforme
L’anemia falciforme è un disturbo genetico che influenza la funzionalità dei globuli rossi, dando origine a un difetto nella fornitura di ossigeno a tutti gli organi. Sebbene esistano alcuni trattamenti efficaci in grado di ridurre i sintomi causati da questa malattia, il processo decisionale è complesso e supportato in modo inadeguato. La missione del progetto INNOVHEM, finanziato dall’UE, è quella di migliorare la cura clinica dei pazienti affetti da anemia falciforme, migliorandone la qualità della vita. A tal fine, i ricercatori stanno sviluppando una soluzione basata sull’intelligenza artificiale (IA) che prende in considerazione parametri biologici e clinici della malattia allo scopo di assistere i medici nel loro compito di proporre un piano di trattamento personalizzato.
Obiettivo
INNOVHEM is a french start-up that has been incorporated in October 2019 which develops new and relevant diagnostic tools to tackle Sickle cell disease. Sickle Cell Disease is a very severe disease and is the most frequent genetic disease over the world, affecting around 5 million people. Despite this disease has been discovered at the beginning of the 20th century, there is still several unmet needs to tackle it.
In resource-poor countries, about 90% of children are estimated to die before the age of 5. In Europe, more than 60 000 people are affected. Their life expectency is shortened to around 45 years old and 80% of physicians say that they lack support tools for treatment decision. In addition, SCD is associated to high clinical costs. At INNOVHEM, we are developing a solution which is a combination of biomarkers, specifically adapted to the physiopathology of the disease, with articial intelligence. This solution will help the physicians to propose a personalized medical care to the patients and it will also help the development of new effective treatments. This will deeply improve health of Sickle cell patients. As an example of impacts, one of the short-term goals is to avoid 20% of emergency visits, this sole effect will save $ 30 million / year in Europe.
During the first year of activity, INNOVHEM showed a high commercial traction, that allows to sign contracts for a total amonut of 800k euros . We also enter into several partnerships with leading clinical and university centers for sickle cell disease.
Our mission is to improve clinical care of Sickle cell patients and improve their lives. A financial support will help us to build our access market strategy and our growth in Europe.
Parole chiave
Programma(i)
- HORIZON.3.2 - European innovation ecosystems Main Programme
Argomento(i)
Invito a presentare proposte
(si apre in una nuova finestra) HORIZON-EIE-2021-SCALEUP-01
Vedi altri progetti per questo bandoMeccanismo di finanziamento
HORIZON-CSA - HORIZON Coordination and Support ActionsCoordinatore
91000 Evry-Courcouronnes
Francia